Multiple sclerosis - A review of recent advances in diagnostics and treatments
DOI:
https://doi.org/10.12775/QS.2023.14.01.004Keywords
multiple sclerosis, pathogenesis, immunology, genetics, diagnostics, treatmentAbstract
Introduction: Multiple sclerosis is a common chronic neuroinflammatory disease of the CNS with an autoimmune basis. It is the most common non-traumatic disorder that leads to disability in young adults.
It occurs 3x more often in women. The quality of life of people suffering from multiple sclerosis is often significantly reduced.
Objective: The purpose of this review is to analyze the latest information on the characteristics, diagnosis
and treatment of patients with multiple sclerosis.
Methods and matherials: A review of the literature available in the PubMed database published between
2016 and 2022, using the following keywords: "multiple sclerosis"; "pathogenesis"; "immunology"; "genetics"; “diagnostics” and "treatment."
State of knowledge: Currently, there is no effective cure for multiple sclerosis but therapeutic options have increased over the past few years. Unfortunately, the effectiveness of disease-modifying therapies is too low and they cannot stop the progressive neurodegenerative process in the CNS. A recent development is the option of MS therapy using stem cells. This is to overcome the loss of nerve cells and increase the repair capacity of endogenous myelin.
Conclusions: Although knowledge of the pathogenesis of the disease has advanced tremendously in recent years and many new therapeutic options have emerged, our knowledge is still incomplete. This poses a challenge for creating more drugs and halting the progression of the disease.
References
Marcus R. What Is Multiple Sclerosis? JAMA. 2022 Nov 22;328(20):2078. doi: 10.1001/jama.2022.14236. PMID: 36413229.
Rodríguez Murúa S, Farez MF, Quintana FJ. The Immune Response in Multiple Sclerosis. Annu Rev Pathol. 2022 Jan 24;17:121-139. doi: 10.1146/annurev-pathol-052920-040318. Epub 2021 Oct 4. PMID: 34606377.
Patsopoulos NA. Genetics of Multiple Sclerosis: An Overview and New Directions. Cold Spring Harb Perspect Med. 2018 Jul 2;8(7):a028951. doi: 10.1101/cshperspect.a028951. PMID: 29440325;
PMCID: PMC6027932.
Liu R, Du S, Zhao L, Jain S, Sahay K, Rizvanov A, Lezhnyova V, Khaibullin T, Martynova E, Khaiboullina S, Baranwal M. Autoreactive lymphocytes in multiple sclerosis: Pathogenesis and treatment target. Front Immunol. 2022 Sep 23;13:996469. doi: 10.3389/fimmu.2022.996469. PMID: 36211343; PMCID: PMC9539795.
Ruiz F, Vigne S, Pot C. Resolution of inflammation during multiple sclerosis. Semin Immunopathol. 2019 Nov;41(6):711-726. doi: 10.1007/s00281-019-00765-0. Epub 2019 Nov 15. PMID: 31732775;
PMCID: PMC6881249.
Tarlinton RE, Martynova E, Rizvanov AA, Khaiboullina S, Verma S. Role of Viruses in the Pathogenesis
of Multiple Sclerosis. Viruses. 2020 Jun 13;12(6):643. doi: 10.3390/v12060643. PMID: 32545816;
PMCID: PMC7354629.
Robinson WH, Steinman L. Epstein-Barr virus and multiple sclerosis. Science. 2022 Jan 21;375(6578):
-265. doi: 10.1126/science.abm7930. Epub 2022 Jan 13. PMID: 35025606.
Ochoa-Repáraz J, Kirby TO, Kasper LH. The Gut Microbiome and Multiple Sclerosis. Cold Spring Harb Perspect Med. 2018 Jun 1;8(6):a029017. doi: 10.1101/cshperspect.a029017. PMID: 29311123;
PMCID: PMC5983160.
Pierrot-Deseilligny C, Souberbielle JC. Vitamin D and multiple sclerosis: An update. Mult Scler Relat Disord. 2017 May;14:35-45. doi: 10.1016/j.msard.2017.03.014. Epub 2017 Mar 29. PMID: 28619429.
Reich DS, Lucchinetti CF, Calabresi PA. Multiple Sclerosis. N Engl J Med. 2018 Jan 11;378(2):169-180.
doi: 10.1056/NEJMra1401483. PMID: 29320652; PMCID: PMC6942519.
Yamout BI, Alroughani R. Multiple Sclerosis. Semin Neurol. 2018 Apr;38(2):212-225. doi: 10.1055/s-0038-1649502. Epub 2018 May 23. PMID: 29791948.
Tornic J, Panicker JN. The Management of Lower Urinary Tract Dysfunction in Multiple Sclerosis. Curr Neurol Neurosci Rep. 2018 Jun 28;18(8):54. doi: 10.1007/s11910-018-0857-z. PMID: 29956001;
PMCID: PMC6022518.
Schiess N, Calabresi PA. Multiple Sclerosis. Semin Neurol. 2016 Aug;36(4):350-6. doi: 10.1055/s-0036-1585456. Epub 2016 Sep 19. PMID: 27643903.
Doshi A, Chataway J. Multiple sclerosis, a treatable disease. Clin Med (Lond). 2016 Dec;16(Suppl 6):s53-s59. doi: 10.7861/clinmedicine.16-6-s53. PMID: 27956442; PMCID: PMC6329568.
Travers BS, Tsang BK, Barton JL. Stwardnienie rozsiane: diagnoza, terapia modyfikująca przebieg choroby i rokowanie. Aust J Gen Pract. 2022 kwiecień;51(4):199-206. doi: 10.31128/AJGP-07-21-6103. PMID: 35362004.
Filippi M, Preziosa P, Rocca MA. MRI in multiple sclerosis: what is changing? Curr Opin Neurol. 2018 Aug;31(4):386-395. doi: 10.1097/WCO.0000000000000572. PMID: 29952834.
Göbel K, Kleinschnitz C, Meuth SG. Advances in Multiple Sclerosis 2017. Int J Mol Sci. 2018 Mar 19;19(3):901. doi: 10.3390/ijms19030901. PMID: 29562661; PMCID: PMC5877762.
Kalb R, Brown TR, Coote S, Costello K, Dalgas U, Garmon E, Giesser B, Halper J, Karpatkin H, Keller J, Ng AV, Pilutti LA, Rohrig A, Van Asch P, Zackowski K, Motl RW. Exercise and lifestyle physical activity recommendations for people with multiple sclerosis throughout the disease course. Mult Scler. 2020 Oct;26(12):1459-1469. doi: 10.1177/1352458520915629. Epub 2020 Apr 23. PMID: 32323606; PMCID: PMC7575303.
Piehl F. Current and emerging disease-modulatory therapies and treatment targets for multiple sclerosis.
J Intern Med. 2021 Jun;289(6):771-791. doi: 10.1111/joim.13215. Epub 2020 Dec 20. PMID: 33258193; PMCID: PMC8246813.
McCarthy C, Thorpe J. Some recent advances in multiple sclerosis. J Neurol. 2016 Sep;263(9):1880-6. doi: 10.1007/s00415-016-8124-1. Epub 2016 Apr 25. PMID: 27113601.
Hauser SL, Cree BAC. Treatment of Multiple Sclerosis: A Review. Am J Med. 2020 Dec;133(12):1380-1390.e2. doi: 10.1016/j.amjmed.2020.05.049. Epub 2020 Jul 17. PMID: 32682869; PMCID: PMC7704606.
Swallow E, Patterson-Lomba O, Yin L, Mehta R, Pelletier C, Kao D, Sheffield JK, Stonehouse T, Signorovitch J. Comparative safety and efficacy of ozanimod versus fingolimod for relapsing multiple sclerosis. J Comp Eff Res. 2020 Mar;9(4):275-285. doi: 10.2217/cer-2019-0169. Epub 2020 Jan 17. PMID: 31948278.
Piehl F. Current and emerging disease-modulatory therapies and treatment targets for multiple sclerosis.
J Intern Med. 2021 Jun;289(6):771-791. doi: 10.1111/joim.13215. Epub 2020 Dec 20. PMID: 33258193; PMCID: PMC8246813.
Jakimovski D, Kolb C, Ramanathan M, Zivadinov R, Weinstock-Guttman B. Interferon β for Multiple Sclerosis. Cold Spring Harb Perspect Med. 2018 Nov 1;8(11):a032003. doi: 10.1101/cshperspect.a032003. PMID: 29311124; PMCID: PMC6211378.
Lamb YN. Ocrelizumab: A Review in Multiple Sclerosis. Drugs. 2022 Feb;82(3):323-334. doi: 10.1007/s40265-022-01672-9. Epub 2022 Feb 22. PMID: 35192158; PMCID: PMC8862399.
Genc B, Bozan HR, Genc S, Genc K. Stem Cell Therapy for Multiple Sclerosis. Adv Exp Med Biol. 2019;1084:145-174. doi: 10.1007/5584_2018_247. PMID: 30039439.
Maillart E, Lubetzki C. Multiple sclerosis in 2020: un bon cru. Lancet Neurol. 2021 Jan;20(1):12-13. doi: 10.1016/S1474-4422(20)30441-5. PMID: 33340473; PMCID: PMC7837095.
Axisa PP, Hafler DA. Multiple sclerosis: genetics, biomarkers, treatments. Curr Opin Neurol. 2016 Jun;29(3):345-53. doi: 10.1097/WCO.0000000000000319. PMID: 27058221; PMCID: PMC7882195.
Williamson EM, Chahin S, Berger JR. Vaccines in Multiple Sclerosis. Curr Neurol Neurosci Rep. 2016 Apr;16(4):36. doi: 10.1007/s11910-016-0637-6. PMID: 26922172.
Kelly H, Sokola B, Abboud H. Safety and efficacy of COVID-19 vaccines in multiple sclerosis patients.
J Neuroimmunol. 2021 Jul 15;356:577599. doi: 10.1016/j.jneuroim.2021.577599. Epub 2021 May 4. PMID: 34000472; PMCID: PMC8095041.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Klaudia Wiśniewska, Agnieszka Ostańska, Adrianna Szafran, Wiktor Terelak, Marcin Ciechański, Edyta Witkowska, Laura Piasek, Grzegorz Godek, Kacper Więcław, Katarzyna Stańko
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 3869
Number of citations: 0